Patents Assigned to Madera Therapeutics, LLC
  • Protein kinase regulators
    Patent number: 11091477
    Abstract: Novel compounds and pharmaceutically acceptable salts capable of modulating the activity of kinases, including Akt, ERK and MEK. Such modulation affects biological functions, for example, by inhibiting cell proliferation and/or inducing apoptosis. Also provided are pharmaceutical compositions and medicaments, comprising the compounds or salts of the invention, alone or in combination with other therapeutic agents or palliative agents.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: August 17, 2021
    Assignee: Madera Therapeutics, LLC
    Inventor: Edwin J. Iwanowicz
  • Protein kinase regulators
    Patent number: 11091483
    Abstract: Novel compounds and pharmaceutically acceptable salts capable of modulating the activity of kinases, including Akt, ERK and MEK. Such modulation affects biological functions, for example, by inhibiting cell proliferation and/or inducing apoptosis. Also provided are pharmaceutical compositions and medicaments, comprising the compounds or salts of the invention, alone or in combination with other therapeutic agents or palliative agents.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: August 17, 2021
    Assignee: Madera Therapeutics, LLC
    Inventor: Edwin J. Iwanowicz
  • Imidazo-pyrimidone compounds, and preparation method and application thereof
    Patent number: 10526332
    Abstract: Compounds of formula (I), imidazopyrimidine ketones, as well as preparations and applications thereof. Compounds and pharmaceutically acceptable salts thereof which stimulate the body to produce tumor necrosis factor-related apoptosis-inducing ligands, while avoiding the drawbacks of existing cancer treatments based on recombinant proteins and antibodies. Thus, they can provide novel options for the treatment of related tumors.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 7, 2020
    Assignee: Madera Therapeutics, LLC
    Inventors: Ruo Xu, Yunyong Liu